Skip to Main Content

Paper Details

Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer.
Nat Commun
44
2021
AR, AR-negative NEPC, AR-negative prostate cancer, AR-negative tumors, Ascl1, MYCN, N-Myc, N-Myc cistrome, NEPC, Pou2f3, Rb1, adenocarcinoma, advanced prostate cancer, androgen, androgen receptor, cell populations, chromatin, men, mouse, neuroendocrine prostate cancer, patients, prostate adenocarcinoma, transcriptome, tumors
Author NameAffiliation
Michael SigourosCaryl and Israel Englander Institute for Precision Medicine, New York-Presbyterian Hospital
Rohan Bareja
Rohan BarejaInstitute for Computational Biomedicine
Andrea Sboner
Andrea SbonerInstitute for Computational Biomedicine
Andrea SbonerMeyer Cancer Center
Andrea SbonerCaryl and Israel Englander Institute for Precision Medicine, New York-Presbyterian Hospital
Andrea Sboner
Andrea SbonerCaryl and Israel Englander Institute for Precision Medicine, New York-Presbyterian Hospital
Andrea SbonerMeyer Cancer Center
Andrea SbonerInstitute for Computational Biomedicine
Olivier ElementoCaryl and Israel Englander Institute for Precision Medicine, New York-Presbyterian Hospital
Olivier ElementoInstitute for Computational Biomedicine
Olivier Elemento
Olivier ElementoMeyer Cancer Center
Olivier ElementoCaryl and Israel Englander Institute for Precision Medicine, New York-Presbyterian Hospital
Olivier ElementoMeyer Cancer Center
Olivier Elemento
Olivier ElementoInstitute for Computational Biomedicine
Scott T TagawaMeyer Cancer Center
Scott T Tagawa
David M NanusMeyer Cancer Center
David M Nanus
Massimo Loda
Massimo LodaMeyer Cancer Center
Himisha BeltranDana Farber Cancer Institute
Himisha BeltranDana Farber Cancer Institute
Brian D Robinson
Brian D Robinson
Brian D RobinsonCaryl and Israel Englander Institute for Precision Medicine, New York-Presbyterian Hospital
Brian D RobinsonMeyer Cancer Center
David S Rickman
David S RickmanMeyer Cancer Center
  • 1 - 33

Datasets

Release 1.2